MedTrace Logo

Evaluation of the Effectiviness of Two Different Bupivacaine Concentrations of the Pericapsular Nerve Group (PENG) Block

NCT05921110 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2023-06-27

No results posted yet for this study

Summary

The use of regional anaesthesia techniques as part of multimodal analgesia in hip surgeries improves postoperative analgesia. PENG (Pericapsular nerve group) block is an effective motor sparing analgesia technique used in hip surgeries. The purpose of this study was to assess the efficacy of PENG block in terms of analgesic requirements and pain density in patients undergoing hip surgery, using two different concentrations of local anaesthetic.

Conditions

  • Hip Fractures
  • Postoperative Pain

Interventions

PROCEDURE

Pericapsular nerve group block 0,25%

Used for postoperative anagesia after hip operations under spinal anaesthesia. Drug: Bupivacaine (Block Drug) For block performances, 0,25% Bupivacaine will be used at 20 ml volume.

PROCEDURE

Pericapsular nerve group block 0,16%

Used for postoperative anagesia after hip operations under spinal anaesthesia. Drug: Bupivacaine (Block Drug) For block performances, 0,16% Bupivacaine will be used at 20 ml volume

Sponsors & Collaborators

  • Abant Izzet Baysal University

    collaborator OTHER

  • Ilker Ital

    lead OTHER

Principal Investigators

  • Fatma Saridemir · Bolu Abant İzzet Baysal Medical School

  • Hamit Yoldas · Bolu Abant İzzet Baysal Medical School

  • Ilker Ital · Bolu Abant İzzet Baysal Medical School

  • Cengiz Isık · Bolu Abant İzzet Baysal Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-15
Primary Completion
2023-11-30
Completion
2023-11-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05921110 on ClinicalTrials.gov